Literature DB >> 1361568

Inhibition of adenylate cyclase in the locus coeruleus mediates the hypnotic response to an alpha 2 agonist in the rat.

C Correa-Sales1, C Nacif-Coelho, K Reid, M Maze.   

Abstract

Recently, we determined that the transduction mechanism for the hypnotic response to dexmedetomidine, a highly selective alpha 2 agonist, resides in the locus coeruleus (LC) of the rat. Candidates for the effector mechanism of this alpha 2 adrenoceptor-mediated hypnotic response include inhibition of adenylate cyclase, which has been shown to be pivotal to the cellular response of alpha 2 agonists in some, but not in all, cases. The LC of rats were stereotaxically cannulated with an indwelling catheter, and after the 2nd day, the hypnotic response to 7 micrograms of dexmedetomidine into the LC (an effective hypnotic dose for 95% of animals) was tested. Other groups of rats were pretreated with the permeable nonhydrolyzable cyclic AMP (cAMP) analog, dibutyryl cAMP (dB cAMP), at a dose of 0.2 to 1.2 ng into the LC, or 2.75 to 275 micrograms.kg-1 i.p. rolipram, a cAMP-specific phosphodiesterase inhibitor, and the hypnotic response to 7 micrograms of dexmedetomidine into the LC was tested. Both dB cAMP and rolipram reversed the hypnotic response to dexmedetomidine. To test for the specificity of these hypnotic-reversing perturbations, rats were pretreated with Rp-adenosine-3',5'-cyclic phosphorothioate, a cAMP-dependent protein kinase inhibitor, and the experiments were repeated. The hypnotic-reversing property of either dB cAMP or rolipram could be prevented by blocking cAMP-dependent protein kinase ("A" kinase) activity with Rp-adenosine-3',5'-cyclic phosphorothioate.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1361568

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Assessing the emetic potential of PDE4 inhibitors in rats.

Authors:  A Robichaud; C Savoie; P B Stamatiou; N Lachance; P Jolicoeur; R Rasori; C C Chan
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

2.  Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis.

Authors:  Annette Robichaud; Panagiota B Stamatiou; S-L Catherine Jin; Nicholas Lachance; Dwight MacDonald; France Laliberté; Susana Liu; Zheng Huang; Marco Conti; Chi-Chung Chan
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

3.  Applications of Dexmedetomidine in Palliative and Hospice Care.

Authors:  Rafael Lemus; Natalie L Jacobowski; Lisa Humphrey; Joseph D Tobias
Journal:  J Pediatr Pharmacol Ther       Date:  2022-09-26

Review 4.  From Bench to Bedside and Back Again: A Personal Journey with Dexmedetomidine.

Authors:  Mervyn Maze
Journal:  Anesthesiology       Date:  2016-09       Impact factor: 7.892

5.  Antisense technology reveals the alpha2A adrenoceptor to be the subtype mediating the hypnotic response to the highly selective agonist, dexmedetomidine, in the locus coeruleus of the rat.

Authors:  T Mizobe; K Maghsoudi; K Sitwala; G Tianzhi; J Ou; M Maze
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

6.  The effects of DEX premedication on volatile induction of mask anesthesia (VIMA) and sevoflurane requirements.

Authors:  Ayse Mizrak; Suleyman Ganidagli; Mehri T Cengiz; Unsal Oner; Vahap Saricicek
Journal:  J Clin Monit Comput       Date:  2013-02-12       Impact factor: 2.502

Review 7.  Contribution of sedative-hypnotic agents to delirium via modulation of the sleep pathway.

Authors:  Robert D Sanders; Mervyn Maze
Journal:  Can J Anaesth       Date:  2010-12-18       Impact factor: 5.063

8.  A Comparative Study of Effect of 0.25% Levobupivacaine with Dexmedetomidine versus 0.25% Levobupivacaine in Ultrasound-Guided Supraclavicular Brachial Plexus Block.

Authors:  Lakshmi S Iyer; Shreyas S Bhat; H N Nethra; H N Vijayakumar; K Sudheesh
Journal:  Anesth Essays Res       Date:  2022-03-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.